Pfizer (NYSE:PFE) Stock Price Down 1.5% – What’s Next?

Posted by Brenda Bartman on Jun 8th, 2026

Pfizer Inc. (NYSE:PFE – Get Free Report) traded down 1.5% during mid-day trading on Monday . The stock traded as low as $25.60 and last traded at $25.6550. 39,882,553 shares were traded during trading, a decline of 3% from the average session volume of 41,152,750 shares. The stock had previously closed at $26.04.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer reported Phase 2b data for its obesity drug berobenatide showing about 15.9% weight loss, reinforcing the company’s case for building a meaningful GLP-1/obesity franchise and supporting expectations for a larger late-stage development program. Article Title
Positive Sentiment: The U.S. FDA approved an expanded indication for HYMPAVZI, allowing it to be used in additional hemophilia A or B patient populations, including pediatric patients ages 6 to 11 and patients with inhibitors. This expands the drug’s commercial opportunity and adds a near-term growth driver. Article Title
Positive Sentiment: Options activity jumped sharply, with traders buying unusually large volumes of PFE call options. That suggests some investors are positioning for continued upside or a volatility-driven move higher.
Neutral Sentiment: Pfizer also presented at Goldman Sachs’ 47th Annual Global Healthcare Conference, but no major new company-specific catalyst was highlighted in the transcript excerpt provided. Article Title
Negative Sentiment: Broader commentary about rising capital spending turning “cash cows” into weaker investments may remind investors that large pharma names like Pfizer still face pressure from heavy R&D and capital needs, though this is more of a sector-theme concern than a direct Pfizer-specific hit. Article Title

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a research report on Thursday, February 12th. Wolfe Research restated an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. Royal Bank Of Canada restated an “underperform” rating and set a $25.00 price target on shares of Pfizer in a research report on Monday, April 20th. Finally, UBS Group restated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $28.82.

Check Out Our Latest Research Report on PFE

Pfizer Trading Down 1.5%

The stock has a market capitalization of $146.22 billion, a P/E ratio of 19.58 and a beta of 0.34. The firm’s 50 day moving average price is $26.62 and its 200 day moving average price is $26.30. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio is 131.30%.

Hedge Funds Weigh In On Pfizer

A number of institutional investors have recently bought and sold shares of the stock. Vermillion Wealth Management Inc. raised its stake in Pfizer by 19.4% in the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 382 shares in the last quarter. Triad Wealth Partners LLC raised its stake in Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after buying an additional 386 shares in the last quarter. Eagle Capital Management LLC raised its stake in Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after buying an additional 390 shares in the last quarter. ETF Store Inc. raised its stake in Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 396 shares in the last quarter. Finally, Delta Financial Advisors LLC raised its stake in Pfizer by 1.6% in the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock worth $709,000 after buying an additional 398 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

About Pfizer

(Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.